Zhi Guo | Stem Cell Research | Best Researcher Award

Posted on by Cell Biologist

Prof. Dr Zhi Guo | Stem Cell Research | Best Researcher Award

Prof. Dr Zhi Guo | Department of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital | China

Dr. Zhi Guo is a distinguished expert in hematology with over 25 years of clinical and academic experience. Currently serving as Director, Academic Leader, Chief Physician, and Professor at the Department of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital, he has been instrumental in advancing hematologic malignancy treatments in China. With extensive expertise in hematopoietic stem cell transplantation, Dr. Guo has successfully performed more than 1,300 transplant cases. He began his career at the PLA Army General Hospital, serving there for nearly two decades before transitioning to his current role. A prolific researcher, he has authored over 10 peer-reviewed publications and five books, contributing substantially to the understanding of CAR-T therapy, gut microbiota, and transplantation immunology. He is an active member of major national and international hematology associations and plays a vital role in formulating clinical consensus and guidelines in China.

publication profile:

Scopus

Strengths for the Award:

Dr. Zhi Guo exemplifies the qualities of an outstanding medical researcher and clinician. With nearly 25 years of clinical experience in hematology and over 20 years in hematopoietic stem cell transplantation, he stands out as a national leader in this field. His performance of more than 1,300 transplants, along with a strong academic footprint, including 10 SCI-indexed publications in 2024–2025, demonstrates both depth and innovation in his research. He has also contributed to national expert consensus and clinical guidelines, particularly in CAR-T therapy and intestinal microecology. Dr. Guo’s leadership roles across national academic committees and his active membership in the American Society of Hematology further highlight his international impact and collaborative influence.

Areas for Improvement:

While Dr. Guo’s achievements in clinical practice and research are significant, opportunities exist to increase global visibility by expanding his research collaborations internationally and publishing in higher-impact journals beyond regional scopes. Additionally, while five books have been authored, the addition of patents or translational innovations could enhance his profile in the realm of research commercialization and practical medical technologies.

Education :

Dr. Zhi Guo holds a strong academic background in clinical medicine and medical research. He earned his Bachelor’s degree in Medicine from Tongji Medical College in 2000. Subsequently, he pursued his postgraduate medical studies at the Third Military Medical University, completing it in 2007. His academic journey culminated with the attainment of a Doctor of Medicine (MD) degree from Wuhan University of Science and Technology. His education laid a strong foundation in hematology and clinical research methodologies. Each step in his educational path was marked by an emphasis on academic rigor and clinical competence, preparing him for a leadership role in medical science and hematologic research. His multidisciplinary background has enabled him to integrate clinical insights with advanced laboratory-based innovations, contributing to national-level guidelines and the development of cutting-edge CAR-T cell therapies and transplantation techniques.

Experience :

Dr. Zhi Guo brings nearly 25 years of clinical, academic, and leadership experience in the field of hematology. He began his professional journey at the PLA Army General Hospital, where he served from 2000 to 2018. During this period, he honed his clinical and procedural expertise in managing complex hematologic disorders. Since 2018, he has been leading the Department of Hematology at Huazhong University of Science and Technology Union Shenzhen Hospital as Director, Academic Leader, and Chief Physician. His rich experience includes more than 1,300 hematopoietic stem cell transplantations, encompassing autologous, allogeneic, and CAR-T integrated therapies. His leadership extends beyond clinical care, as he also mentors postgraduate medical students and leads multiple national and institutional research projects. Dr. Guo’s practical experience is balanced with his strategic contributions to medical consensus formulation and research-driven policy initiatives in cancer and immune-hematological disorders.

Research Focus :

Dr. Zhi Guo’s research centers on hematologic malignancies and hematopoietic stem cell transplantation, particularly the integration of cellular immunotherapy such as CAR-T cell treatments. His recent work includes pioneering anti-CD19, anti-CD7, and anti-BCMA CAR-T therapies for lymphomas and leukemias. Additionally, he has investigated the interplay between microbiota and immune modulation in transplantation, highlighting the role of gut and oral microbiomes in patient outcomes. His contributions have influenced the development of clinical guidelines for microbiota-related diagnostics and treatments in oncology. With more than 10 high-impact journal publications and ongoing projects in translational medicine, Dr. Guo’s work combines laboratory innovation with patient-centered applications. He has also authored expert consensus documents and national guidelines, helping shape China’s hematology and transplantation protocols. His commitment to interdisciplinary collaboration, clinical innovation, and translational research underscores his leading role in advancing modern hematology.

Publications Top Notes:

  1. 🧬 In vitro validation of anti-CD19 CAR-T cells with LSD1 shRNA for DLBCL – Front Immunol, 2025

  2. 🩸 Case of T-ALL treated with chemo + anti-CD7 CAR-T (retroviral vector) – Front Immunol, 2025

  3. 👶 Shaping oral/intestinal microbiota & immunity in first 1,000 days of life – Front Pediatr, 2025

  4. 💩 Fecal microbiota transplantation in acute GVHD treatment – J Cancer Res Ther, 2024

  5. 🔬 Chinese consensus on gut microecology lab standards – Exp Ther Med, 2024

  6. 🧪 2024 Chinese guidelines for intestinal microecology in cancer – J Cancer Res Ther, 2024

  7. 🧫 First MM case treated with ASCT + anti-BCMA CAR-T (retrovirus) – Heliyon, 2024

  8. 🧾 Rapid response in relapsed FL to anti-CD19 CAR-T with CMV – Int Immunopharmacol, 2024

  9. 🦷 Prognostic impact of oral microbiome in cancer survival – meta-analysis – Syst Rev, 2024

  10. 🧍‍⚕️ Expert consensus on gut microbiome & hematopoietic stem cell transplantation – Clin Transplant, 2024

Conclusion:

In conclusion, Dr. Zhi Guo is highly suitable for the Best Researcher Award. His combination of clinical excellence, academic leadership, and impactful research in hematology and stem cell transplantation positions him among the top contributors in this specialized field. With ongoing research in CAR-T cell therapies, microbiota influence on transplantation, and immuno-oncology, Dr. Guo continues to shape the future of hematologic cancer care. Recognizing his contributions with this award would be both fitting and encouraging for continued innovation in this vital area of medicine.

 

Sibel Elif Gultekin | Stem Cell Research | Best Researcher Award

Posted on by Cell Biologist

Prof. Dr. Sibel Elif Gultekin | Stem Cell Research | Best Researcher Award

Prof. Dr. Sibel Elif Gultekin , Gazi University Faculty of Dentistry , Turkey

Prof. Dr. Sibel Elif Gültekin is an accomplished academic and researcher in Oral Pathology and Periodontology at Gazi University, Ankara. With dual DDS and Ph.D. degrees, she has led the Department of Oral Pathology for a decade and significantly contributed to understanding oral cancer, odontogenic lesions, and HPV-related pathologies. Her collaborative research with institutions such as UCSF and the University of Cologne has yielded numerous high-impact publications and advancements in oral diagnostics. She has authored two books and published over 96 articles in reputable journals. A prominent figure in national and international research boards, Dr. Gültekin has also played a pioneering role in establishing oral pathology as a specialty in Türkiye. Her work integrates molecular biology with clinical oral health, emphasizing innovation, collaboration, and translational science. Recognized globally, she continues to mentor emerging scholars while contributing to policy-making and curriculum development in dental education.

Publication Profile:

Orcid

✅ Strengths for the Award:

  • Extensive Research Portfolio: Over 96 peer-reviewed publications, with 40 in SCI journals, reflects consistent scholarly productivity and scientific depth.

  • Citation Impact: High citation indices (Google Scholar: 1,381, h-index: 17) demonstrate strong academic influence and relevance in the field of molecular oral pathology.

  • International Collaborations: Long-term, productive collaborations with prestigious institutions including the University of Cologne and UCSF underline global recognition and trust.

  • Focused Expertise: Specialization in oral epithelial dysplasia, HPV-associated oral/oropharyngeal cancers, and molecular mechanisms of odontogenic lesions aligns closely with cutting-edge cell biology and translational research.

  • Academic Leadership: Established the Department of Oral Pathology in Türkiye and mentored future scientists, contributing to both academic infrastructure and talent development.

  • Editorial and Advisory Roles: Active roles in scientific boards and journals underscore her influence in shaping academic discourse and peer-review standards.

🛠 Areas for Improvement:

  • Patent Development: Incorporating translational research into patentable diagnostics or therapeutics would enhance practical impact and innovation scoring.

  • Funding & Industry Engagement: Broader engagement with industry-funded projects and clinical trials could further expand her work’s translational potential and outreach.

  • Global Clinical Guidelines Influence: Participation in international committees that develop clinical practice guidelines would strengthen policy-level impact.

🎓 Education:

Prof. Dr. Sibel Elif Gültekin pursued her initial dental training and later earned dual Ph.D. degrees in Periodontology and Oral Pathology, demonstrating a unique interdisciplinary depth. She completed her undergraduate and doctoral education at Gazi University, Faculty of Dentistry, Ankara. Her academic journey also included prestigious international research fellowships at the University of Cologne (Germany) and the University of California, San Francisco (UCSF, USA), where she focused on advanced molecular mechanisms in oral diseases, especially HPV-related oncogenesis and tissue regeneration. Her training reflects a blend of clinical excellence and a strong foundation in molecular biology and translational research. Through a blend of local and global academic exposure, Dr. Gültekin has acquired cutting-edge knowledge and technical expertise, which she continues to leverage in her teaching and research. Her international education and academic credentials have contributed to building strong scientific bridges between Türkiye and the global dental research community.

🧪 Professional Experience:

Prof. Dr. Sibel Elif Gültekin has over 20 years of academic and research experience in dentistry, with a specialized focus on Oral Pathology and Periodontology. She currently serves as a full professor and head of the Oral Pathology Department at Gazi University Faculty of Dentistry, a position she has held for more than a decade. Dr. Gültekin has actively engaged in research collaborations with renowned institutions such as the University of Cologne and UCSF, significantly contributing to the fields of oral cancer and molecular diagnostics. She has completed over 50 research projects and advised numerous postgraduate theses. As a scientific advisor and board member for several national and international journals and associations, she plays a pivotal role in shaping academic and clinical standards. Her editorial appointments and leadership in symposia highlight her commitment to academic excellence and global research integration. She continues to lead innovation in oral health education and research policy.

🔬 Research Focus:

Dr. Gültekin’s research centers on the molecular pathology of oral diseases, with particular emphasis on oral epithelial dysplasia, HPV-induced oral/oropharyngeal cancers, and the genetic underpinnings of odontogenic tumors and cysts. Her studies have investigated biomarkers such as p16, PDCD4, and VIM3, enabling improved early detection and classification of oral malignancies. She is also involved in exploring microsatellite instability, loss of heterozygosity, and B-RAF/MEK inhibition in the context of oral and maxillofacial tumors. A major dimension of her work includes periodontal tissue regeneration and molecular mechanisms of tooth development, which bridges clinical periodontology with developmental biology. Her research is translational, aiming to bridge bench-to-chairside pathways, and supports the development of personalized diagnostic and therapeutic strategies. With over 1,300 citations and active involvement in global research initiatives, her investigations have significantly influenced current understanding and clinical approaches in oral pathology.

📄 Publications Top Notes:

  1. 🧬 Microsatellite Instability and Loss of Heterozygosity as Prognostic Markers in Oral Squamous Cell Carcinoma – Genes, Chromosomes and Cancer (2024)

  2. 💊 Efficiency of B-RAF-/MEK-inhibitors in B-RAF mutated Ameloblastoma: Case report and review – Heliyon (2023)

  3. 🦷 Kişiselleştirilmiş Diş Hekimliği (Personalized Dentistry) – ADO Klinik Bilimler Dergisi (2023)

  4. 🧪 Apoptosis Related PDCD4: Promising Novel Biomarker for Early Detection of Oral Cancer – ADO Klinik Bilimler Dergisi (2022)

  5. 🧫 PD-L1 Expression and CD8+ Lymphocyte Infiltration Predict Outcome in Oropharyngeal Squamous Cell Carcinoma – IJMS (2020)

🔍 Conclusion:

Prof. Dr. Sibel Elif Gültekin stands out as an exceptional and qualified candidate for the Best Researcher Award. Her work in the field of oral pathology and molecular diagnostics not only contributes to advancing science but also bridges basic research with clinical applications. With a solid foundation in interdisciplinary science, international collaboration, and academic leadership, she exemplifies the values the award seeks to honor. Her achievements strongly align with the criteria of sustained research excellence, innovation, and global impact.